Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Theravance Biopharma, Inc.    TBPH   KYG8807B1068

THERAVANCE BIOPHARMA, INC.

(TBPH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/14/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
25.08(c) 24.83(c) 25.295(c) 25.9(c) 25.77(c) Last
575 360 973 558 256 121 518 709 497 786 Volume
-0.12% -1.00% +1.87% +2.39% -0.50% Change
More quotes
Financials (USD)
Sales 2019 61,1 M
EBIT 2019 -246 M
Net income 2019 -236 M
Debt 2019 154 M
Yield 2019 -
Sales 2020 105 M
EBIT 2020 -225 M
Net income 2020 -204 M
Debt 2020 99,8 M
Yield 2020 -
P/E ratio 2019 -6,25x
P/E ratio 2020 -7,56x
EV / Sales2019 28,8x
EV / Sales2020 16,2x
Capitalization 1 604 M
More Financials
Company
Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of... 
Sector
Pharmaceuticals
Calendar
02/24Earnings Release
More about the company
Surperformance© ratings of Theravance Biopharma, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on THERAVANCE BIOPHARMA, INC.
02/18THERAVANCE BIOPHARMA : Announces Presentations at Upcoming Investor Conferences
PR
02/13THERAVANCE BIOPHARMA : to Report Fourth Quarter and Full Year 2019 Financial Res..
PR
02/11THERAVANCE BIOPHARMA : Announces Pricing of Public Offering of Ordinary Shares
PR
02/10THERAVANCE BIOPHARMA : Announces Proposed Public Offering of Ordinary Shares
PR
01/07THERAVANCE BIOPHARMA : Announces Presentation at the 38th Annual J.P. Morgan Hea..
PR
2019THERAVANCE BIOPHARMA : Pfizer in License Agreement
DJ
2019THERAVANCE BIOPHARMA : Announces Dosing of First Patient in Phase 2 Allergen Cha..
PR
2019THERAVANCE BIOPHARMA : to Present at Two Upcoming Investor Conferences
PR
2019THERAVANCE BIOPHARMA : Summary ToggleTheravance Biopharma to Present at the 2019..
PU
2019THERAVANCE BIOPHARMA : to Present at the 2019 Credit Suisse Healthcare Conferenc..
PR
2019THERAVANCE BIOPHARMA : Summary ToggleTheravance Biopharma, Inc. Reports Third Qu..
PU
2019THERAVANCE BIOPHARMA, INC. : Reports Third Quarter 2019 Financial Results and Pr..
PR
2019THERAVANCE BIOPHARMA : Summary ToggleTheravance Biopharma to Report Third Quarte..
PU
2019THERAVANCE BIOPHARMA : to Report Third Quarter 2019 Financial Results on Novembe..
PR
2019THERAVANCE BIOPHARMA : Summary ToggleTheravance Biopharma and Mylan to Present N..
PU
More news
News in other languages on THERAVANCE BIOPHARMA, INC.

- No features available -

More news
Sector news : Pharmaceuticals - NEC
02/21Marriott Hires Former Merck CIO as Tech Chief
DJ
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/21DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
02/21ALLERGAN : Form 8.3 -
DJ
02/21ABBVIE : Form 8.3 -
DJ
More sector news : Pharmaceuticals - NEC
Chart THERAVANCE BIOPHARMA, INC.
Duration : Period :
Theravance Biopharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERAVANCE BIOPHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 35,00  $
Last Close Price 25,77  $
Spread / Highest target 113%
Spread / Average Target 35,8%
Spread / Lowest Target -30,2%
EPS Revisions
Managers
NameTitle
Rick E. Winningham Chairman & Chief Executive Officer
Andrew Asa Hindman Chief Financial Officer & Senior Vice President
Brett K. Haumann Chief Medical Officer & SVP-Clinical Development
Robert V. Gunderson Independent Director
Burton Gordon Malkiel Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERAVANCE BIOPHARMA, INC.-0.46%1 604
JOHNSON & JOHNSON1.71%395 024
ROCHE HOLDING AG10.08%300 195
NOVARTIS2.89%218 568
MERCK AND COMPANY-9.47%209 636
PFIZER-8.50%197 679